TY - JOUR
T1 - Sequential therapy in the treatment of locally advanced noninflammatory breast cancer
AU - Strom, Eric A.
AU - Dhingra, Kapil
N1 - Funding Information:
From the Departments of Radiotherapy and Breast Medical Ontology, The University of Texas M.D. Anderson Cancer Center, Houston. Supported in part by National Cancer Institute, Department of Health and Human Services Grants No. CA06294 and CA16627. K.D. is a recipient of a Clinical Oncology Career Development Award flora the American Cancer Society. Address reprint requests to Eric A. Strom, MD, Department of Radiotherapy, Box 97, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. Copyright 9 1994 by W.B. Saunders Company 1053-4296/94/0404-0002505.00/0
PY - 1994/10
Y1 - 1994/10
N2 - Optimal care of patients with locally advanced breast cancer requires the use and thoughtful integration of all effective modalities of treatment. A number of alternative combinations of surgery, chemotherapy, and radiation have been promoted, each with its own particular advantages and shortcomings. The advantages of sequenced, multimodality therapy of locally advanced, noninflammatory breast cancer include (1) the ability to convert nonresectable tumors to resectable ones, (2) early institution of systemic therapy, (3) in vivo evaluation of tumor response with the potential for optimization of therapy, and (4) relatively low morbidity rates with the ability to render most patients disease-free at their primary site. The results of this treatment strategy are discussed.
AB - Optimal care of patients with locally advanced breast cancer requires the use and thoughtful integration of all effective modalities of treatment. A number of alternative combinations of surgery, chemotherapy, and radiation have been promoted, each with its own particular advantages and shortcomings. The advantages of sequenced, multimodality therapy of locally advanced, noninflammatory breast cancer include (1) the ability to convert nonresectable tumors to resectable ones, (2) early institution of systemic therapy, (3) in vivo evaluation of tumor response with the potential for optimization of therapy, and (4) relatively low morbidity rates with the ability to render most patients disease-free at their primary site. The results of this treatment strategy are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0028088793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028088793&partnerID=8YFLogxK
U2 - 10.1016/S1053-4296(05)80092-X
DO - 10.1016/S1053-4296(05)80092-X
M3 - Article
AN - SCOPUS:0028088793
SN - 1053-4296
VL - 4
SP - 217
EP - 225
JO - Seminars in radiation oncology
JF - Seminars in radiation oncology
IS - 4
ER -